Is Global Health Overvalued or Undervalued Right Now?
- September 1, 2026
- Posted by: Kunal Singla
- Category: Market
Global Health CMP Rs 1,480.10 (31 Aug 2026), up 0.54%. PE 71.59 vs industry PE 68.00. ROE 14.05%. 52W range Rs 956.00 to Rs 1,544.00.
Quick Answer
Global Health trades at a price to earnings ratio of 71.59 against an industry average of 68.00, which puts the stock close to fair value on a simple multiple basis rather than clearly overvalued or undervalued. The company’s 14.05% return on equity and Rs 147.34 book value per share fit broadly within its sector’s range. Whether Global Health is overvalued or undervalued right now is less about a wide valuation gap and more about how its growth and margins evolve from here.
Is Global Health overvalued or undervalued right now is a question worth asking given how its price to earnings ratio compares with the rest of its sector. At the current market price of Rs 1,480.10, the stock trades roughly 4.1% below its 52 week high of Rs 1,544.00 and about 54.8% above its 52 week low of Rs 956.00.
Global Health’s share price moved up 0.54% in Monday’s session to Rs 1,480.10, against a market capitalisation of Rs 39,538 Cr. This article looks at the numbers, the PE ratio, price to book, return on equity, debt levels and recent earnings trends, that determine whether the current price reflects fair value or a stretched multiple.
Click Here – Get Free Investment Predictions
Global Health Valuation Metrics: Where Does the Stock Stand?
| Valuation Metric | Global Health |
|---|---|
| CMP (31 Aug 2026) | Rs 1,480.10 |
| Market Cap | Rs 39,538 Cr |
| P/E Ratio | 71.59 |
| Industry P/E | 68.00 |
| P/B Ratio | 9.98 |
| Sector Average P/B (hospitals and diagnostics) | 8.16 |
| Return on Equity (ROE) | 14.05% |
| Sector Average ROE (hospitals and diagnostics) | 23.42% |
| EPS (TTM) | Rs 20.54 |
| Book Value per Share | Rs 147.34 |
| Debt to Equity | 0.30 |
| Dividend Yield | 0.03% |
| Sector Average Dividend Yield (hospitals and diagnostics) | 0.23% |
| 52 Week High / Low | Rs 1,544.00 / Rs 956.00 |
The headline number here is the price to earnings ratio. At 71.59, the Global Health PE ratio is 1.05 times the industry average of 68.00. Measured against its hospitals and diagnostics sector peers, the gap widens further on other measures too: a P/B of 9.98 against a sector average of 8.16, and an ROE of 14.05% against a sector average of 23.42%.
Is Global Health Overvalued Based on Its P/E Ratio?
Based on the P/E ratio alone, Global Health looks fairly valued. The stock’s PE of 71.59 sits close to the industry average of 68.00, which suggests the market is pricing the business roughly in line with its sector rather than at a premium or a discount. That leaves the read on whether Global Health is overvalued or undervalued more dependent on its growth trajectory than on the PE ratio itself.
Check Global Health’s Live Fundamentals on the Univest Screener
Global Health’s Financial Growth and Profitability
Global Health’s revenue moved from Rs 3,771.29 crore in FY2025 to Rs 4,508.86 crore in FY2026, a change of 19.6%. Net profit grew from Rs 481.32 crore to Rs 554.07 crore over the same period, a swing of roughly 15.1%.
The Global Health share price has moved alongside this earnings trend, which is part of why the stock now trades at 1.05 times the industry PE of 68.00 rather than a flat multiple.
Download the Univest iOS App or Univest Android App to track Global Health’s live share price and valuation ratios.
Arguments That Global Health Could Be Overvalued
- Rich price to book: A P/B of 9.98 is well above the sector average of 8.16.
- Low dividend yield: At 0.03%, the stock offers little income cushion if the growth story slows.
- Limited margin of safety: At Rs 1,480.10, the stock is only 4.1% below its 52 week high of Rs 1,544.00, leaving less room for error if earnings disappoint.
Arguments That Support the Premium Valuation
- Low leverage: A debt to equity ratio of 0.30 gives Global Health a comparatively strong balance sheet.
- 52 week range context: At Rs 1,480.10, the stock is 54.8% above its 52 week low of Rs 956.00, showing it has already found some support at lower levels.
Verdict: Is Global Health Overvalued or Undervalued Right Now?
On balance, Global Health looks fairly valued rather than clearly overvalued or undervalued. Its PE of 71.59 sits close to the industry average of 68.00, and its 14.05% ROE and other ratios do not point to a significant mispricing either way. The more useful question for investors from here is less about the current multiple and more about whether earnings growth accelerates or slows.
What Could Change This Valuation Picture for Global Health?
Two broad scenarios could shift this valuation call on Global Health in either direction. On the upside, an improvement in return ratios or growth that pushes the stock’s PE of 71.59 toward a premium over the industry average of 68.00. On the downside, a deterioration in the numbers that pulls the PE below the industry average of 68.00 instead. Investors watching the Global Health share price over the next few quarters should track whether reported ROE holds near 14.05% and whether the PE gap versus the industry average of 68.00 widens or narrows, since both will matter more to the eventual answer than the current price point on its own.
Conclusion
Global Health’s numbers point to a stock that is fairly valued on headline multiples. Investors tracking the Global Health share price should watch whether earnings growth can keep pace with the current PE of 71.59, since that gap remains the single biggest variable in whether the stock is undervalued, fairly priced, or overvalued from here. This article is for informational purposes only and is not investment advice.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Global Health Valuation
Is Global Health overvalued or undervalued right now?
Ans. Based on a PE ratio of 71.59 against an industry average of 68.00, Global Health currently looks fairly valued on relative valuation. Its 14.05% ROE is an important part of the picture alongside the PE ratio.
What is Global Health’s current PE ratio?
Ans. Global Health’s price to earnings ratio stands at 71.59, compared with an industry average PE of 68.00.
What is Global Health’s return on equity?
Ans. Global Health generates a return on equity of 14.05%, against a sector average of 23.42% among hospitals and diagnostics peers.
What is Global Health’s 52 week high and low?
Ans. Global Health’s 52 week high is Rs 1,544.00 and its 52 week low is Rs 956.00. The stock currently trades around Rs 1,480.10, roughly 4.1% below its high.
Does Global Health have high debt?
Ans. Global Health carries a debt to equity ratio of 0.30, which is low for its sector.
What is Global Health’s dividend yield?
Ans. Global Health offers a dividend yield of 0.03% at the current share price.
Is Global Health a good stock to buy at current levels?
Ans. Global Health’s current valuation suits investors who agree with the fairly valued read on its PE ratio and are comfortable with the trade-off between its return ratios and its price. This is for informational purposes only and is not investment advice.
What is Global Health’s price to book ratio?
Ans. Global Health trades at a price to book ratio of 9.98, compared with a sector average of 8.16 among hospitals and diagnostics peers.
